Table II.
Popular targets in solid tumor treatment.
| Tumor site/origin | Potential therapeutic target for treatment |
|---|---|
| Skin | GD2, VEGFR |
| Head and neck | EGFR |
| Brain | EGFRvIII, HER2, IL-13RA |
| Nerve cells | GD2, PHOX2B |
| Lungs | CEA, EGFR, HER2, MSLN, CLDN18, ROR, GD2 |
| Breast | GD2, EGFR, ROR, TEM8, HER2, MSLN |
| Stomach | CEA, HER2, EpCAM, CLDN18, MSLN |
| Liver | CEA, GPC3, HER2 |
| Pancreas | CEA, MSLN, MUC1, HER2, CLDN18, EGFR |
| Ovary | CEA, MSLN, L1CAM, MUC16, CLDN18, PSCA |
| Kidney | CAIX, VEGFR |
| Prostate | PSMA, PSCA |
| Colon | CEA, GUCY2C, CLDN18 |
| Soft tissue | GD2, HER2 |
GD2, diasialoganglioside 2; VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant III; HER2, human epidermal growth factor receptor 2; IL-13RA, interleukin-13RA; PHOX2B, paired-like homebox 2B; MSLN, mesothelin; CLDN18, claudin 18; ROR, tyrosine protein kinase transmembrane receptor; TEM8, tumor endothelial marker 8; CEA, carcinoembryonic antigen; EpCAM, epithelial cell adhesion molecule; GPC3, glycipan 3; MUC1, mucin; L1CAM, L1 cell adhesion molecule; PSCA, prostate stem cell antigen; CAIX, carbonic anhydrase IX; PSMA, prostate-specific membrane antigen; GUCY2C, guanylate cyclase 2C.